NCT01092663View on ClinicalTrials.gov

The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus

NACompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Colesevelam HCl

Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.

DRUG

Sitagliptin

Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.

Trial Locations (3)

33014

Clinical Pharmacology of Miami, Miami

78209

Healthcare Discoveries, LLC d/b/a ICON Development Solutions, San Antonio

94110

University of California, San Francisco, San Francisco

Sponsors

Lead Sponsor

KineMed
All Listed Sponsors
lead

KineMed

INDUSTRY

NCT01092663 - The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter